In a challenging year for the biotech sector, Fulgent Genetics Inc . (NASDAQ:FLGT) stock has touched a 52-week low, dipping ...

Opus Genetics, Inc., a pharmaceutical company specializing in preparations with a market capitalization of $35.67 million, has announced the date for its 2025 Annual Meeting of Stockholders. According ...

Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during reproduction.

A groundbreaking study reveals evidence that, in Iron Age Britain, land inheritance followed the female line, with husbands ...

From fighting diseases to determining why you can't stand cilantro, genetics are the silent architects of your life. Here's ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Established in 1908, the Aquebogue site is the last commercial duck farm on Long Island, once world-renowned for its ducks.

A study of occupational status published in Nature Human Behavior identifies 106 genetic variants, the importance of the ...

Researchers at deCODE genetics have developed a groundbreaking DNA map, revealing the intricate process of genetic recombination during reproduction. This map highlights areas of DNA that undergo ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

在其他近期新闻中，Fulgent Genetics公布了2024年第三季度财报，总收入为7170万美元，低于去年同期的8470万美元。这一下降与COVID-19检测收入减少有关。然而，公司在精准诊断收入方面同比增长18.8%，特别是在生殖健康和肿瘤学领域。公司还更新了药物候选品FID-007和FID-022的进展，前者已进入II期临床试验，后者正在朝着年底前提交新药研究申请的目标迈进。

Myriad Genetics, Inc. (MYGN)股价已触及新的52周低点，跌至12.16美元，公司正面临充满挑战的市场环境。根据 InvestingPro ...